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Background: The Study to Assess Long-term Opioid Medication Effectiveness (SALOME) is a two-stage phase III,
single site (Vancouver, Canada), randomized, double blind controlled trial designed to test if hydromorphone is as
effective as diacetylmorphine for the treatment of long-term illicit opioid injection. Recruiting participants for clinical
trials continues to be a challenge in medical and addiction research, with many studies not being able to reach the
planned sample size in a timely manner. The aim of this study is to describe the recruitment strategies in SALOME,
which offered appealing treatments but had limited clinic capacity and no guaranteed post-trial continuation of the
treatments.
Methods: SALOME included chronic opioid-dependent, current illicit injection opioid users who had at least
one previous episode of opioid maintenance treatment. Regulatory approvals were received in June 2011 and
recruitment strategies were implemented over the next 5 months. Recruitment strategies included ongoing open
communication with the community, a consistent and accessible team and participant-centered screening. All
applicants completed a pre-screening checklist to assess prerequisites. Applicants meeting these prerequisites were
later contacted to commence the screening process.
Results: A total of 598 applications were received over the two-year recruitment period; 130 were received on the
first day of recruitment. Of these applicants, 485 met prerequisites; however, many could not be found or were not
reached before recruitment ended. For the 253 candidates who initiated the screening process, the average time
lapse between application and screening date was 8.3 months (standard deviation [SD] = 4.44) and for the 202
randomized to the study, the average processing time from initial screen to randomization was 25.9 days
(SD = 37.48; Median = 15.0).
Conclusions: As in prior trials offering injectable diacetylmorphine within a supervised model, recruiting participants
for this study took longer than planned. The recruitment challenges overcome in SALOME were due to the high
number of applicants compared with the limited number that could be randomized and treated. Our study
emphasizes the value of integrating these strategies into clinical addiction research to overcome study-specific barriers.
Trial registration: ClinicalTrials.gov: NCT01447212.
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Opioid dependency remains to be a major public health
concern in North America and worldwide. Abstinence
oriented treatment has shown to benefit small propor-
tions of people struggling with opioid-dependence [1];
opioid substitution and maintenance treatment continues
to be the best approach to stop the use of illicit opioids
[2]. Oral methadone is the most used and studied of these
treatments with demonstrated effectiveness at reducing
illicit drug use and improving health and psychosocial out-
comes [3]. Few other opioids besides oral methadone have
been studied for the treatment of opioid dependency.
Among these other opioids, injectable diacetylmorphine
(i.e., pharmaceutical-grade heroin [DAM]), dispensed in a
controlled and medically supervised setting, has shown to
be effective in the treatment of long-term opioid injectors
not sufficiently benefitting from oral methadone [4].
Despite that several randomized clinical trials (RCT)
in Europe and Canada have demonstrated the effective-
ness of DAM, very few countries have adopted it as part
of their addiction treatment system. There is a clear need
for alternative treatments as effective as injectable DAM
that health care systems could adopt to attract and retain
long-term street opioid injectors into treatment. One such
alternative could be HDM [5] and the SALOME (Study to
Assess Long-term Opioid Medication Effectiveness) study
was designed to test this. SALOME is a randomized double
blind controlled trial testing if injectable HDM (a licenced
pain medication) is as effective as DAM for the treatment
of long-term opioid-dependent individuals who are not
benefitting sufficiently from conventional treatments, and
if a transition to the oral equivalent of HDM and DAM
after six-months is as effective as the injection form.
Recruiting participants for clinical trials can be slow
and difficult, and much effort is dedicated to reach the
required sample size within a reasonable timescale and
budget [6-8]. For example, a review of RCTs across a
wide array of medical conditions in the United Kingdom
showed that nearly half of the trials received an extension
of some kind due to the struggle to recruit the planned
sample size [9]. Although it is unclear why some trials re-
cruit more effectively than others, it has been suggested
that studies providing treatments that are desired and/or
only available through the trial, or studies comparing two
similar treatments, might have fewer challenges with re-
cruitment [10-13].
Methodological and empirical studies regarding re-
cruitment in clinical trials for addiction are sparse. Some
evidence suggests that RCTs in this field face similar
challenges to those aforementioned in medical research
[14]. However, addiction treatment trialists also encoun-
ter barriers specific to this field [15]. For example, mo-
tivation to participate may be more challenging when
recruiting participants who have generally unstable dailyliving conditions and difficulties attending appointments
[16]. Studies with similar populations have addressed the
importance of building trust with the target population,
support them to keep appointments, and provide ancillary
services for other needs as part of their recruitment strat-
egies [17]. Moreover, traditionally employed strategies for
motivating participation, such as telephone reminders [18],
may not be feasible with this population. These unique fac-
tors necessitate discussion amongst addictions researchers
to better inform strategies tailored to benefit recruitment
in forthcoming addiction trials.
Context specific challenges related to recruitment for
RCTs with DAM treatment have also been documented.
Every RCT testing DAM has had longer than expected
recruitments and in some cases had to enrol fewer par-
ticipants than planned [19]. A variety of context-specific
reasons explain this. For example, in Spain, by the time
the study was able to start enrolling participants, injec-
tion street heroin use had dropped drastically (heroin
users were smoking it instead) and the sample size could
not be reached [20]. In a Belgian study, one of the main
reasons street heroin users did not apply was the concern
over the limited length of access to the study medications
[19]. In our prior study, NAOMI (North American Opiate
Medication Initiative), the site in Vancouver received more
than 1,000 applications; however, the study criteria did not
reflect the realities of the intended sample population and
most applicants did not even meet minimal requirements
at first contact [21].
SALOME compared two treatments appealing to the
target population that were only available through the
study. Despite the advantages that this scenario presents
for recruitment, experience in prior RCTs testing DAM
suggested that offering desirable treatments might not
be sufficient to meet the planned sample size within a rea-
sonable time. The aim of the present study is to describe
the recruitment experiences of the SALOME trial and dis-
cuss the strategies that were employed. This paper could
inform the development of recruitment strategies for up-




SALOME is a two-stage phase III, single site (Vancouver),
randomized, double blind controlled trial involving a total
of 202 participants. The study population is defined as
chronic, opioid-dependent, injection drug users who are
currently injecting and who have attempted at least one
previous episode of opioid maintenance treatment. Spe-
cific eligibility criteria included: a) minimum age of nine-
teen years; b) currently residing in the greater Vancouver
area of British Columbia, Canada; c) current regular use of
injectable opioids; d) at least two verified prior addiction
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stitution treatment; e) at least five years or more of illicit
opioid use; f ) poor health or psychosocial functioning; and
g) provision of fully informed consent. Participants were
excluded if they did not meet inclusion criteria, had med-
ical conditions contraindicated for treatment with inject-
able opioids or criminal justice involvement resulting in
prolonged incarceration. The study was reviewed and
received ethical approval from the University of British
Columbia/Providence Health Care research ethics board.
Sample size requirements for the study were calculated
based on illicit heroin use as the primary outcome. Using
data derived from the results of our prior NAOMI trial, a
non-inferiority design with an expected decline of 20 days
(standard deviation = 11.0) of illicit heroin use from base-
line, a margin of 4 days, a power of 0.90, an expected loss-
to-follow-up rate of 0.05 and a one-sided alpha level of
0.05, requires 202 participants (101 per group) for phase I.
With a sample size of n = 202, we can expect that approxi-
mately 172 participants will enter into phase II. Under the
same assumptions as above, this will yield a non-inferiority
trial with power = 0.86.
In phase I, half of the 202 participants were randomized
to receive injectable DAM, and the other half to receive
injectable HDM. In phase II, participants still receiving
treatment in phase I were randomized to continue injec-
tion treatment exactly as in phase I on a blinded basis or
to switch to the oral equivalent of the same medication
(DAM or HDM).
DAM or HDM, either orally or injected, could only be
prescribed and self-administered in the study clinic under
supervision of health care providers, up to three times
daily. Study treatments were provided for six months in
each phase, followed by a one-month period during which
participants still being treated with DAM or HDM were ta-
pered and transitioned to other treatments available in the
community (e.g., methadone). Upon entry into the trial,
each participant had access to a defined range of primary
care services matched to the prevalent conditions seen in
injection drug users. A psychosocial support worker was
also assigned who provided individual counselling services
and case management (i.e., coordinated inter-disciplinary
services such as housing and disability support).
Clinic capacity and timeline
To be able to operate, the SALOME trial site requires an
Exemption under Section 56 of the Canadian federal
Controlled Drugs and Substances Act. This allows health
care staff and researchers to use controlled narcotics for
scientific purposes. Several security features are needed in
a clinic in order to receive such an exemption and only
one, the Vancouver clinic that was used in our prior NA-
OMI study, met these requirements at the time. The study
clinic was planned to accommodate up to 95 participantsreceiving injectable medications. Once study participants
completed the treatment or were switched to oral medica-
tions (phase II) or dropped out from the study, new par-
ticipants could be screened and allocated into the study.
The limited clinic capacity resulted in a varying enrolment
pace of six to twenty participants per month, instead of
four to five per week as planned.
It later became clear that in order to meet the service
needs of the participants, the clinic could best operate with
no more than 85 participants receiving injectable medica-
tions per day. In addition to clinic capacity, three external
events halted enrolment for five months. First, a national
shortage of hydromorphone occurred four months into the
study (Figure 1a) and caused a two month halt to recruit-
ment while the research and clinical care teams developed
a strategy and gained the necessary approvals for the study
pharmacy to manufacture hydromorphone for participants
only. Due to air quality issues requiring construction in the
building where the study clinic is placed (an old bank), re-
cruitment was halted for one month to reduce the physical
demands on the clinic. Finally, changes in the Provincial
PharmaNet recording of all drug prescription practices that
would have led to the potential unblinding of clinic health
care workers also caused a two month pause to recruit-
ment while the clinical team worked with the authorities
to develop a site specific protection feature. These impedi-
ments and the reduced clinic capacity delayed reaching the
sample size by seven months approximately.
Community engagement
Regulatory approvals were received in June 2011 and re-
cruitment strategies were implemented over the next five
months. A team was assembled and included the principal
investigator (EOJ), research coordinators (KL; KM), the
lead nurse, lead physician (SM), and communications dir-
ector. This team engaged in recruitment collaboratively
and remained consistent throughout the study. One of the
Research Coordinators (KL), who had over a decade of
experience working with the target population in the
neighbourhood where the study was conducted, was fully
devoted to overseeing recruitment.
Before recruitment opened, the team established a con-
veniently located research office, telephone recruitment
number, email address, and study website. As part of ef-
forts to reach every opioid user in Vancouver, we identified
agencies, not-for-profit groups and health care providers
that work with the target population and would be able to
assist relaying information about the trial. These agencies
were contacted and offered an opportunity to have the
team provide an information session for staff and clients.
Over these months, we hosted approximately 20 formal
information sessions with various agencies, including drug
user groups (e.g., Vancouver Area Network of Drug Users,
Drug Users Resource Centre), the research ethics board,
Figure 1 Cumulative recruitment, screening and enrolment to the SALOME trial. a) Cumulative recruitment into the SALOME trial. Number
of applicants, ineligibles, and participants randomized to the SALOME trial over time. b) Cumulative screening of candidates in the SALOME trial.
Number of candidates and randomized participants screened for the SALOME trial over time.
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town Eastside Women’s Center), social workers, legal
agencies, health officers, and politicians. These sessions
included a 20 to 30 minute verbal presentation of the
study and time for questions. Common discussion topics
included eligibility criteria, the duration of treatment and
transition planning at the end of the study. Informationpackages were distributed either at the end of the session
or in lieu of; materials included relevant publications from
the NAOMI trial, contact information and answers to fre-
quently asked questions. The team continued to provide
updates and information sessions during the study as re-
quested by these groups or as new information about the
study became available.
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was also established and is comprised of various stake-
holders in the community. The purpose of the CAB is to
provide guidance and feedback to the SALOME team
with respect to accrual, retention, compliance, access, and
ethical issues surrounding study. The CAB also serves as a
link between the community and the SALOME team and
has been a place for discussions of strategies for continu-
ation of provision of study treatments.
These community engagement activities provided the
team with an opportunity to learn of the perceived
strengths and weaknesses of the trial and their implica-
tions for recruitment and the study itself. Strengths
included the benefit of the medication and the need for
alternative treatments. The lack of guaranteed continu-
ation of study treatments was the main worry expressed
by the community and patients. Also, some addictions
physicians expressed concern over patients leaving suc-
cessful treatments and binging in street drug in order to
qualify for the study.
Recruitment process
Since we experienced a combination of positive interest
in SALOME as well as opposition, the team prepared
the first day of recruitment (December 19, 2011 between
9am and 5pm) taking into account that the number of
applicants could be high or low. In addition to opening
the recruitment telephone number, recruitment tables
were set up at three key agencies serving the target
population. Information about this first day was dis-
played in advance at several local agencies and the CAB.
In order to filter minimal requirements without signing
consent and engaging in full screening, applicants were
interviewed at first contact with a pre-screening checklist,
which assessed prerequisites for initiating screening and
collected contact information. The recruitment telephone
number was the primary method for applying to the study
after the first day of recruitment. A chronological num-
bered list of applicants was created and used to determine
their processing order. Once an applicant’s number was
reached on this list, the applicant was re-contacted. Upon
reaching the applicant, the on-file pre-screening checklist
was reviewed and the applicant was asked if he or she was
still interested in participating. If so, an appointment
was made to begin the screening process. If an applicant
could not be found, the chronological order of their ap-
plication was not displaced. For example, candidates
who were incarcerated when the team initially contacted
them were able to reconnect and begin the screening
process upon release.
Screening to the study required a minimum of three
appointments, each lasting an hour or longer in duration.
There were no costs to participants and at each stage in
the screening process candidates were provided a modeststipend for their time amounting to $35 CAD over the
three visits (average hourly wage in British Columbia is
$10.50 CAD). During the first visit, candidates signed the
informed consent, and the process of verifying eligibility
criteria was started. At the second screening visit, candi-
dates completed the baseline questionnaires. Candidates
meeting criteria up to the end of the second screening
visit were scheduled to meet with the study physician for a
full medical examination and confirmation of all criteria.
This visit was multi-disciplinary and patient centered; can-
didates were introduced to the health care providers and
services available at the clinic (reception, nurses, physi-
cians, psychosocial team) and a psychosocial assessment
was completed. This process was effective for screening
and providing an orientation to all aspects of the care
available at the clinic.
Following the medical examination and confirmation
of all criteria, the study physician notified the research
team of participant eligibility. A member of the research
team then randomized the participant using the trial
randomization database. Randomization notifications were
then distributed to the clinic coordinator and pharmacy
manager for preparation of the participant’s treatment
initiation.
Analysis
Mean, standard deviation [SD] and proportions were used
to describe time lapse, the flow of applications and meet-
ing or not prerequisites or study criteria for applicants
and candidates.
Results
From December 2011 to December 2013, a total of 598
(196 female, 397 male, 4 transgender-female and 1 with
missing gender) applications were received for the SAL-
OME trial. Figure 1a and 1b show the progress of the ap-
plications over the two-year period. On the first day 130
individuals applied to the study (Figure 1a). These appli-
cants were randomly assigned a number that was used to
determine their processing order. Individuals who applied
after these 130 applicants were added to this list in chrono-
logical order. After the first day the number of applicants
continued to increase steadily over the two-year period at a
pace faster than the study had capacity to enrol. Therefore,
efforts to actively promote recruitment (e.g., recruitment
posters, recruitment tables) were halted.
Figure 2 shows the flow of the applications through to
randomization. From the total number of applicants, 485
(81.1% of total 598 who applied) met the prerequisites on
the pre-screening checklist. Among those eligible for
screening at this stage, 159 were female, 321 were male, 4
were transgender-female and one applicant’s gender was
missing. For various reasons shown in Figure 2, we could
not re-assess 185 of these 485 applicants (e.g., could not
Figure 2 SALOME screening flow chart. Stages of screening in the SALOME trial and number of applicants at each stage.
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cants were excluded for no longer meeting study prerequi-
sites or no longer being interested in participating. The
rate of applicants not meeting the prerequisites on the
pre-screening checklist throughout the two-year recruit-
ment period remained constant (Figure 1a).
A total of 253 (52.2% of those who met prerequisites
on the pre-screening checklist; 76 female, 174 male, 3
transgender-female) candidates signed the informed con-
sent and initiated screening. Due to the limited clinic
capacity and the external situations that halted recruit-
ment, the average time lapse between the point of first
application and first screening visit was 8.3 (SD = 4.44;
Q1 = 6.33; median = 8.67; Q3 = 11.03) months. Their aver-
age age was 44.76 (SD = 9.61; Q1 = 38.0; median = 45.0;
Q3 = 52.0). Thirty candidates (11.8% of those who started
screening; 11 female, 19 male) were excluded due to not
meeting at least one of the inclusion or exclusion criteria.
In addition, 14 (5 female, 9 male) candidates started the
screening process but did not continue for unknown rea-
sons and 7 (1 female, 6 male) expressed that they were no
longer interested in participating in the study. The pri-
mary reasons for exclusion of the 30 candidates was theregularity of current opioid injection (n = 15) and not suf-
ficiently attempted OST or other types of addiction treat-
ment (n = 9). For those eligible candidates, the average
number of days between the first screening visit and
randomization date was 25.95 (SD = 37.48; Q1 = 9.0; me-
dian = 15.0; Q3 = 23.0; Figure 1b). For 28 participants, the
time lapse between first consent and randomization was
more than 30 days, mainly because of challenges main-
taining contact and rescheduling of missed appointments.
Discussion
As in prior trials offering injectable DAM within a su-
pervised model, recruiting participants for this study
took seven months longer. However, this additional time
can be attributed to the extraneous events and limited
clinic capacity. Without these events and with a larger
clinic, recruitment into the trial would have been even
faster than expected.
The challenges that the research team had to overcome
for recruitment into SALOME were due to the high num-
ber of applicants compared with the limited number that
could be randomized and treated. Our recruitment plan
was based on recommendations from recruitment into
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experiences of this research team [21]. The recruitment
strategies that were instrumental in overcoming these
challenges included the community engagement process
[13,22], the consistent, accessible and experienced team
[13] and a participant-centered screening process [12,14].
The community engagement process was highly valu-
able in forming partnerships with key agencies working
with the study population and the patients. A very im-
portant long-term aim of the community engagement
plan was to lay the foundation for future continuation of
supervised injectable treatment. With these partnerships
and their vested interest in this, we had the opportunity to
establish this groundwork. In addition, the CAB was an
important forum for communicating information about
arising barriers as well as devising collaborative strategies
for overcoming them. Throughout the study, there was
open and ongoing communication between the research
team and the community. For example, when a physician
contacted any team member with concerns regarding a
patient being included into the study, meetings were
promptly held to discuss these concerns, while upholding
mutual goals to protect participant/patient autonomy and
the scientific integrity of the study.
The commitment of the community and stakeholders
strengthened our ability to recruit the necessary number
of participants despite the many external barriers affect-
ing recruitment. In addition, having an experienced team
improved communication and the consistency of research
procedures. The team’s cohesion proved beneficial as the
recruitment processes remained constant and the team’s
skills matured over time as barriers continued to arise.
Messages and information relayed about the study were
also homogeneous through media, information materials
and our team. Each message was tailored for the intended
(i.e., participant, health care provider) audience, yet was
consistent to minimize the negative impact arising barriers
might pose to ongoing recruitment. For example, when
we experienced the hydromorphone shortage, we quickly
developed a plan for addressing this issue and a script for
communication. This reduced uncertainty and maintained
community engagement and support.
As in many RCTs, the stages of screening can be a
burden on candidates and SALOME was no exception
to this. In an effort to reduce the loss of candidates
during the screening stages while maintaining scientific
rigor, our procedures aimed to be participant-centered.
Overall interactions with candidates were supportive and
understanding of the daily struggles applicants had. Most
candidates required additional support from the research
team or other agencies to, for example, attend the mul-
tiple appointments required for screening. Sometimes a
team member met candidates at their residence to accom-
pany them to appointments. If the candidate had a socialworker or advocate, the research team worked closely
with that person to support the candidate throughout
the process. The team understood this process as an op-
portunity to engage candidates not just in the study but
also with the health care system, attending to their par-
ticular needs and barriers.
Precise estimates regarding how many applicants were
needed to reach the planned sample size was difficult to
achieve. For example, in many occasions we would have
to go down the ordered applicant list because many
consecutive applicants could not be found. Other times,
they no longer met the prerequisites, were not interested
or were doing well on other treatments. Due to this
unpredictability, the research team continued to accept
new applications until the final sample size was reached.
This decision was made in collaboration with the clinical
team and community advisory board. Like other trials
[17], it was agreed that the opportunity to make contact
with applicants, provide information about the trial and
other treatments was favorable despite the possibility that
recruitment might be complete before we could enrol
them. In our communication with these applicants, they
were informed of their application number, the number
we were presently contacting and our best estimate of the
time lapse or the likelihood of being contacted before
reaching the sample size. Applicants’ desire to apply to the
study despite this and the patience they demonstrated is
indicative of their willingness to access alternative treat-
ments for their long-term opioid dependency.
While our recruitment strategies were effective in
reaching the target sample and allowing us to overcome
extraneous challenges, a limitation of the data collected
in this study is the impossibility to ascertain which strat-
egy or combination of strategies was most influential or
cost-effective. Given that our main strategy for recruit-
ment was based on a strong community engagement plan,
it is difficult to determine which of these activities contrib-
uted to the overall effectiveness of this strategy. For ex-
ample, word of mouth was the primary response received
when applicants were asked how they heard about the
study. With such a response, we are not able to determine
if the sample could have been reached, for example, by fo-
cusing efforts on information sessions to drug user groups
only, without contacting health care workers. Also, the ex-
tensive time lapse caused by the external events makes
comparison with refusal rates from other RCTs problem-
atic. Nevertheless, it is important to note that approxi-
mately one-third of applicants meeting prerequisites were
not invited to initiate screening because we were unable
to find them or because recruitment ended before their
number was reached. Since the pre-screening checklist
data was provided prior to consent, the information col-
lected was very limited and so we have little data about
those we were unable to contact.
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[14,15,17,19,23] regarding the recruitment experiences
and strategies used by addictions trialists who face
barriers unique to this field. The recruitment strategy
yielded the necessary sample size but also provided the
foundation for constructive discussion regarding con-
tinuation of treatment. The strategies put in place in the
SALOME trial and the positive outcomes emphasize the
importance of the time investment in three particular
areas. Well before the trial began, a core team was dedi-
cated to establishing respectful relationships with the
community, which created a supportive system in the
face of unpredictable circumstances that affected the re-
cruitment timeline. A consistent and committed recruit-
ment team was dedicated and maintained through the
study for this task. Finally, frontline research and clin-
ical staff worked toward ensuring applicants had the
support they needed to complete the screening process
and were successfully allocated into the trial. Our expe-
riences reflected in this manuscript could help other re-
searchers in the planning and implementation of future
RCTs in the addictions field with the potential for im-
proving recruitment timelines and retention outcomes.Conclusions
SALOME is searching for evidence-based treatments that
can attract and retain individuals struggling with long-term
opioid dependency into treatment. Although we reached
the target sample size, SALOME recruitment faced serious
challenges specific to the study context. These challenges
were successfully managed through open communication
with the community, a consistent and accessible team and
a participant-centered screening process. Our study em-
phasizes the value of integrating these strategies into clin-
ical addiction research to overcome study-specific barriers.
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